JP7546255B2 - 癌を検出する方法および検出試薬 - Google Patents

癌を検出する方法および検出試薬 Download PDF

Info

Publication number
JP7546255B2
JP7546255B2 JP2021516037A JP2021516037A JP7546255B2 JP 7546255 B2 JP7546255 B2 JP 7546255B2 JP 2021516037 A JP2021516037 A JP 2021516037A JP 2021516037 A JP2021516037 A JP 2021516037A JP 7546255 B2 JP7546255 B2 JP 7546255B2
Authority
JP
Japan
Prior art keywords
antibody
azu1
cancer
group
reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021516037A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020218121A5 (https=
JPWO2020218121A1 (https=
Inventor
幸嗣 植田
なおみ 大西
和丈 辻川
祝夫 野々村
元秀 植村
健太郎 神宮司
則久 大竹
康俊 河合
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japanese Foundation for Cancer Research
Tosoh Corp
University of Osaka NUC
Original Assignee
Japanese Foundation for Cancer Research
Osaka University NUC
Tosoh Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japanese Foundation for Cancer Research, Osaka University NUC, Tosoh Corp filed Critical Japanese Foundation for Cancer Research
Publication of JPWO2020218121A1 publication Critical patent/JPWO2020218121A1/ja
Publication of JPWO2020218121A5 publication Critical patent/JPWO2020218121A5/ja
Application granted granted Critical
Publication of JP7546255B2 publication Critical patent/JP7546255B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4721—Cationic antimicrobial peptides, e.g. defensins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2470/00—Immunochemical assays or immunoassays characterised by the reaction format or reaction type
    • G01N2470/04—Sandwich assay format
    • G01N2470/06—Second binding partner specifically binding complex of analyte with first binding partner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
JP2021516037A 2019-04-24 2020-04-15 癌を検出する方法および検出試薬 Active JP7546255B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019082912 2019-04-24
JP2019082912 2019-04-24
PCT/JP2020/016607 WO2020218121A1 (ja) 2019-04-24 2020-04-15 癌を検出する方法および検出試薬

Publications (3)

Publication Number Publication Date
JPWO2020218121A1 JPWO2020218121A1 (https=) 2020-10-29
JPWO2020218121A5 JPWO2020218121A5 (https=) 2023-04-24
JP7546255B2 true JP7546255B2 (ja) 2024-09-06

Family

ID=72942515

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021516037A Active JP7546255B2 (ja) 2019-04-24 2020-04-15 癌を検出する方法および検出試薬

Country Status (5)

Country Link
US (1) US20220178932A1 (https=)
EP (1) EP3960758A4 (https=)
JP (1) JP7546255B2 (https=)
CN (1) CN113727995A (https=)
WO (1) WO2020218121A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7661767B2 (ja) * 2021-04-28 2025-04-15 東ソー株式会社 細胞外小胞の検出方法
JPWO2024203968A1 (https=) * 2023-03-24 2024-10-03
WO2025197993A1 (ja) * 2024-03-22 2025-09-25 学校法人東邦大学 テトラスパニン１０陽性細胞外小胞の濃縮方法、及びがんを検出する又はがんの予後を予測する方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120077695A1 (en) 2010-09-27 2012-03-29 Somalogic, Inc. Mesothelioma Biomarkers and Uses Thereof
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
US20150141273A1 (en) 2012-04-26 2015-05-21 Stichting Vu-Vumc Biomarkers
US20170153240A1 (en) 2015-11-30 2017-06-01 Sungkwang Medical Foundation Composition, kit, and method for diagnosing and treating ovarian cancer
WO2018079689A1 (ja) 2016-10-28 2018-05-03 公益財団法人がん研究会 バイオマーカー、疾患関連遺伝子の探索方法、及び腎がんマーカー
WO2018217087A1 (en) 2017-05-23 2018-11-29 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Novel stool-based protein biomarkers for colorectal cancer screening

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502522A (en) 1976-11-25 1978-03-01 Gestetner Ltd Stencil ejector on a stencil duplicator
GB0711327D0 (en) 2007-06-12 2007-07-25 Hansa Medical Ab Diagnostic method
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
JP5488885B2 (ja) 2009-10-28 2014-05-14 国立大学法人 東京大学 感染症の疾患マーカー
KR20140107615A (ko) * 2011-12-26 2014-09-04 시오노기 앤드 컴파니, 리미티드 엑소좀 검출용 모노클로날 항체
WO2015083791A1 (ja) * 2013-12-04 2015-06-11 国立研究開発法人理化学研究所 肺癌の検出方法および検出キット
KR102582192B1 (ko) 2014-12-05 2023-09-25 후지필름 가부시키가이샤 Tim 단백질 결합 담체, 당해 담체를 사용한 세포외막소포 및 바이러스의 취득 방법, 제거 방법, 검출 방법 그리고 당해 담체를 포함하는 키트
CN115047182B (zh) * 2017-10-05 2025-03-11 香港科技大学 外泌体分析及癌症诊断方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
US20120077695A1 (en) 2010-09-27 2012-03-29 Somalogic, Inc. Mesothelioma Biomarkers and Uses Thereof
US20150141273A1 (en) 2012-04-26 2015-05-21 Stichting Vu-Vumc Biomarkers
US20170153240A1 (en) 2015-11-30 2017-06-01 Sungkwang Medical Foundation Composition, kit, and method for diagnosing and treating ovarian cancer
WO2018079689A1 (ja) 2016-10-28 2018-05-03 公益財団法人がん研究会 バイオマーカー、疾患関連遺伝子の探索方法、及び腎がんマーカー
WO2018217087A1 (en) 2017-05-23 2018-11-29 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Novel stool-based protein biomarkers for colorectal cancer screening

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JINGUSHI, Kentaro et al.，Extracellular vesicles isolated from human renal cell carcinoma tissues disrupt vascular endothelial cell morphology via azurocidin，International Journal of Cancer，2018年，Vol.142，pp.607-617

Also Published As

Publication number Publication date
EP3960758A4 (en) 2023-02-15
JPWO2020218121A1 (https=) 2020-10-29
EP3960758A1 (en) 2022-03-02
WO2020218121A1 (ja) 2020-10-29
CN113727995A (zh) 2021-11-30
US20220178932A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
US20120271124A1 (en) Thrombospondin Fragments and Uses Thereof In Clinical Assays for Cancer and Generation of Antibodies and Other Binding Agents
US9244079B2 (en) Testing method and testing reagent for angiitis
US9347954B2 (en) Antibody capable of binding to specific region of periostin, and method of measuring periostin using the same
JP6737504B2 (ja) 卵巣明細胞腺癌の検査方法及び検査薬
JP6074676B2 (ja) 組織因子経路阻害因子２（ｔｆｐｉ２）測定による卵巣明細胞腺癌の検査方法および検査薬
EP2515114B1 (en) Method for diagnosing malignant tumor
JP7546255B2 (ja) 癌を検出する方法および検出試薬
JP7127422B2 (ja) 癌を検出する方法及び検出試薬
JP6829444B2 (ja) 去勢抵抗性前立腺癌を検出する方法及び検出試薬
CN110114676A (zh) 肾素浓度的免疫学测定方法
JP7306661B2 (ja) 消化管間質腫瘍を検出する方法および検出試薬
JP2014115186A (ja) 胃癌、肺癌及び／又は食道癌の検出方法
JP6760562B2 (ja) 卵巣明細胞癌患者の予後を予測するための情報提供方法
US9127054B2 (en) Immunoassay of cofilin 1 protein
JP7565046B2 (ja) がんの骨転移を検出する方法及び検出試薬
CN103842504A (zh) 上皮性卵巢癌标志物检测用抗体和上皮性卵巢癌判定方法
JP2014115199A (ja) 胃癌又は食道癌の検出方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240819

R150 Certificate of patent or registration of utility model

Ref document number: 7546255

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150